Jump to Main Content

Programs

Scientific Workshops

The Scientific Workshops are interactive discussions of the latest scientific developments in a particular field of hematology. The following information corresponds to the 2021 workshops expected to take place at the ASH Annual Meeting. Each workshop will be an in-person event with a virtual component. Recordings from each of the workshops will be available on the virtual meeting platform through 11:59 p.m. on December 17, 2021.

All are welcome to attend each workshop. There is no additional fee, but ASH annual meeting registration is required.

December 10, 2021,  2:00 p.m. - 5:00 p.m. Eastern time

This workshop will focus on risk prediction and assessment in non-malignant and malignant hematologic diseases, examining the translation of results of observational and association studies to clinically relevant risk prediction and assessment. Disparities-based risk assessment (including the incorporation of race- and gender into risk assessment and prediction models) will be highlighted across the sessions.

Topics to be covered in this workshop include current knowledge of assessment of risk of primary and secondary malignancies after exposure to radiation, the predictive role of the microbiome in response to therapy for diffuse large B-cell lymphoma, race-based prediction of malignant transformation from monoclonal gammopathy of undetermined significance to multiple myeloma, assessment of venous thromboembolism lipoprotein and stroke risk, risk of thrombosis in myeloma patients related to immunomodulatory drugs, and the role of CHIP in predicting both cardiovascular disease and myeloid malignancies, and development of a cohort of hematologic neoplasms patients to study response to COVID-19 vaccination.

Workshop Schedule


Moderators:

Wendy Cozen , DO,MPH
University of California, Irvine
Irvine,  CA

James R. Cerhan , MD, PhD
Mayo Clinic
Rochester,  MN

Moderator:

James M. Foran , MD
Mayo Clinic Florida
Jacksonville,  FL

Speakers:

James M. Foran , MD
Mayo Clinic Florida
Jacksonville,  FL
Moderator Introduction

Kelly L Bolton , MD
Washington University In St Louis
St Louis,  MO
What Can Clonal Hematopoiesis Teach Us about Secondary Hematologic Malignancies?

Kelly L Bolton , MD
Washington University In St Louis
St Louis,  MO
Q&A

Angela Fleischman , MD, PhD
University of California, Irvine
Irvine,  CA
A Family Registry of MPN and a Potential Predictive Phenotype.

Angela Fleischman , MD, PhD
University of California, Irvine
Irvine,  CA
Q&A

Mohamed L. Sorror , MD, MSc
Fred Hutchinson Cancer Research Center
Seattle,  WA
Risk Assessment, Prediction and Decision Making for Patients with Acute Myeloid Leukemia

Mohamed L. Sorror , MD, MSc
Fred Hutchinson Cancer Research Center
Seattle,  WA
Q&A

Moderators:

Wendy Cozen , DO,MPH
USC Norris Comprehensive Cancer Center
Manhattan Beach,  CA

James R. Cerhan , MD, PhD
Mayo Clinic
Rochester,  MN

Speakers:

James R. Cerhan , MD, PhD
Mayo Clinic
Rochester,  MN
Moderator Introduction

Catherine S. Diefenbach , MD
Perlmutter Cancer Center at NYU Langone Health
New York,  NY
The Role of the Microbiome in Systemic Immunity and Lymphoma Outcome

Catherine S. Diefenbach , MD
Perlmutter Cancer Center at NYU Langone Health
New York,  NY
Q&A

Susan L. Slager , PhD
Mayo Clinic
Rochester,  MN
Risk Assessment in CLL Families: Monoclonal B-Cell Lymphocytosis Incidence and Progression to CLL

Susan L. Slager , PhD
Mayo Clinic
Rochester,  MN
Q&A

Ritu Gupta , MD
Laboratory Oncology, Dr. BRAIRCH
New Delhi,  India
Clinical Impact of Ethnic Differences on Multiple Myeloma Risk Prediction in the Era of Genomics and Novel Agents

Ritu Gupta , MD
Laboratory Oncology, Dr. BRAIRCH
New Delhi,  India
Q&A

Moderator:

Neil A. Zakai , MD,MSc
Fletcher Allen Health Care, University of Vermont
Burlington,  VT

Speakers:

Neil A. Zakai , MD,MSc
Fletcher Allen Health Care, University of Vermont
Burlington,  VT
Introduction to Benign Hematology Risk Prediction and Assessment

Rushad Patell , MBBS
Beth Israel Deaconess Medical Center
Boston,  MA
Prediction of VTE Risk in People with Cancer.

Rushad Patell , MBBS
Beth Israel Deaconess Medical Center
Boston,  MA
Q&A

Monia Marchetti
Hematology Unit, Az Osp SS Antonio e Biagio e Cesare Arrigo
Alessandria,  Italy
VTE Risk Prediction Scores in Clinical Practice Guidelines of Blood Cancers: Advantages and Pitfalls

Monia Marchetti
Hematology Unit, Az Osp SS Antonio e Biagio e Cesare Arrigo
Alessandria,  Italy
Q&A

Pamela L Lutsey , PhD, MPH
University of Minnesota
Minneapolis,  MN
Venous Thromboembolism Epidemiology: Considerations of Risk in Diverse Populations

Pamela L Lutsey , PhD, MPH
University of Minnesota
Minneapolis,  MN
Q&A

Babak Navi , MD,MS
Weill Cornell Medicine
New York,  NY
Thrombophilia and Ischemic Stroke Risk: What Does Epidemiology Teach Us

Babak Navi , MD,MS
Weill Cornell Medicine
New York,  NY
Q&A

Jordan K Schaefer , MD
University of Michigan
Ann Arbor,  MI
Pharmacoepidemiology: Antithrombotics and COVID-19 Outcomes

Jordan K Schaefer , MD
University of Michigan
Ann Arbor,  MI
Q&A

Moderators:

James M. Foran , MD
Mayo Clinic Florida
Jacksonville,  FL

Neil A. Zakai , MD,MSc
Fletcher Allen Health Care, University of Vermont
Burlington,  VT

December 10, 2021,  2:00 p.m. - 5:00 p.m. Eastern time

The importance of identifying individuals with germline mutations that confer susceptibility to hematopoietic malignancies (HM) and bone marrow failure (BMF) is increasingly recognized. Presentations at this workshop will feature updates on scientific progress in disorders of inherited HMs and BMF, highlighting preclinical research aimed at understanding the genes and mechanisms that confer elevated risk, and work that ultimately improves diagnosis and patient management.

This year, sessions will focus on DNA repair pathways; variant interpretation and modeling; new scientific and syndrome discoveries; and ribosomopathies.

This workshop will engage investigators from across the world to foster diverse representation of speakers and topics, a collaborative spirit, and new international collaborations.

Workshop Schedule


Moderator:

Marcin Wlodarski , MD, PhD
St. Jude Children's Research Hospital
Memphis,  TN

Moderators:

Wojciech Mlynarski , Prof, MD, PhD
Medical University of Lodz
Lodz,  Poland

Richa Sharma , MD
St Jude Children's Research Hospital
Memphis,  TN

Speakers:

Edward Chew , PhD
The Walter & Eliza Hall Institute of Medical Research
Parkville,  AUS
MBD4 Associated Neoplasm Syndrome: A Tale of Blood and Guts.

Edward Chew , PhD
The Walter & Eliza Hall Institute of Medical Research
Parkville,  AUS
Live Q&A

Brittany L Griffin , MS, PhD
Cleveland Clinic Foundation
Cleveland,  OH
Germline Biallelic Loss in MBD4 Leading to Early Onset AML with Hyper-Mutator Genomic Signatures

Brittany L Griffin , MS, PhD
Cleveland Clinic Foundation
Cleveland,  OH
Live Q&A

Anase Asom , BS
University of Chicago
Chicago,  IL
The Role of Germline CHEK2 Variants in Hematologic Malignancies

Anase Asom , BS
University of Chicago
Chicago,  IL
Q&A

Hannah Armes , PhD
Queen Mary University of London
London,  United Kingdom
Germline ERCC6L2 Mutations Lead to Impaired Erythropoiesis and Reshaping of the Bone Marrow Niche

Hannah Armes , PhD
Queen Mary University of London
London,  United Kingdom
Live Q&A

Agata Smogorzewska , MD
The Rockefeller University
New York,  NY
Fanconi Anemia Pathway Deficiency Drives Copy Number Variation in Squamous Cell Carcinomas

Agata Smogorzewska , MD
The Rockefeller University
New York,  NY
Live Q&A

Moderators:

Julia T Warren , MD
Washington University School of Medicine
Saint Louis,  MO

Christian P. Kratz , MD
Hannover Medical School
Hannover,  Germany

Speakers:

Sara Lewis , MS, LCGC
St. Jude Children's Research Hospital
Memphis,  TN
Registry for Individuals with Germline SAMD9 and SAMD9L Mutations

Taylor Walker
University of Chicago
Chicago,  IL
Use of a Modified-Delphi Approach to Define the Pleiotropic GATA2-Deficient Phenotype for the Development of Acmg-AMP GATA2 Variant Curation Rules

Parvathy Venugopal , PhD
Centre for Cancer Biology, SA Pathology and University of South Australia
Adelaide,  Australia
Modelling a Germline Mutation to Understand Phenotypes Associated with GATA2 Deficiency Syndrome

Oded Gilad , MD
Tel Aviv University
Tel Aviv,  Israel
Syndromes Predisposing to Leukemia Are a Major Cause of Inherited Cytopenias in Children

Eunice Sindhuvi Edison , PhD
Christian Medical College
Vellore,  Tamilnadu, India
Germline Variants Contribute Significantly to the Pathogenesis of Aplastic Anemia in India

Saumya E Samaraweera , PhD
University of South Australia
Adelaide,  Australia
Childhood Acute Myeloid Leukemia Shows a High Level of Germline Predisposition

Hideki Makishima , MD, PhD
Kyoto University
Kyoto,  JPN
Predisposition and Clinical Impact of DDX41 Germline Mutations in Myeloid Neoplasms

Moderators:

Julia T Warren , MD
Washington University School of Medicine
Saint Louis,  MO

Christian P. Kratz , MD
Hannover Medical School
Hannover,  Germany

Speakers:

Christopher R. Reilly , MD
Dana-Farber Cancer Institute
Boston,  MA
Making Sense out of Missense: The Clinical and Functional Effects of Germline TERT Variants in MDS

Christopher R. Reilly , MD
Dana-Farber Cancer Institute
Boston,  MA
Live Q&A

Timothy M Chlon , PhD
Cincinnati Children's Hospital
Cincinnati,  OH
Modelling DDX41-Mutant MDS

Timothy M Chlon , PhD
Cincinnati Children's Hospital
Cincinnati,  OH
Live Q&A

Anupriya Agarwal , PhD
Oregon Health & Science University
Portland,  OR
Context-Dependent Mechanisms of Defective Hematopoiesis in RUNX1-Familial Platelet Disorder

Anupriya Agarwal , PhD
Oregon Health & Science University
Portland,  OR
Live Q&A

Moderators:

Kasiani C. Myers , MD
Cincinnati Children's Hospital
Cincinnati,  OH

Lionel Blanc , PhD
The Feinstein Institutes for Medical Research
Manhasset,  NY

Speakers:

Deena Iskander , MD
Imperial College London
London,  United Kingdom
Single-Cell Profiling of Human Bone Marrow Progenitors Reveals Mechanisms of Failing Erythropoiesis in Diamond-Blackfan Anemia

Deena Iskander , MD
Imperial College London
London,  United Kingdom
Live Q&A

Yuefeng Tang , PhD
Northwell Health
Manhasset,  NY
Conditional Deletion of Exon 2 in Rps19 Leads to Bone Marrow Failure and Absence of Stress Erythropoiesis in a Mouse Model of Diamond Blackfan Anemia

Yuefeng Tang , PhD
Northwell Health
Manhasset,  NY
Live Q&A

Senthil Velan Bhoopalan , PhD,MBBS
St. Jude Children's Research Hospital
Memphis,  TN
TP53-Dependent Hematopoietic Stem Cell Defect in RPS19 Gene-Edited CD34+ Cells

Senthil Velan Bhoopalan , PhD,MBBS
St. Jude Children's Research Hospital
Memphis,  TN
Live Q&A

Moderators:

Deepak Singhal , MBBS, MD, FRCPA, FRACP
SA Pathology
Adelaide,  Australia

Ana Rio-Machin , PhD
Queen Mary University of London
London,  United Kingdom

Speakers:

Patrycja M Dubielecka , PhD
Warren Alpert Medical School of Brown University
Providence, 
Whole Genome Sequencing Identifies a Recurrent Mutation in Complement Factor I in Primary Myelofibrosis

Patrycja M Dubielecka , PhD
Warren Alpert Medical School of Brown University/Rhode Island Hospital
Providence,  RI
Live Q&A

Anne Davidson , MBBS
The Feinstein Institutes for Medical Research, Northwell Health
Manhasset,  NY
Overexpression of Human TLR8 Causes Fatal Anemia in SLE-Prone Mice Byaltering the Bone Marrow Erythropoietic Niche

Anne Davidson , MBBS
The Feinstein Institutes for Medical Research, Northwell Health
Manhasset,  NY
Live Q&A

Vijay G. Sankaran , MD,PhD
Boston Children's Hospital
Boston,  MA
Insights from Rare Variant Association Studies of Myeloid Malignancies

Vijay G. Sankaran , MD,PhD
Boston Children's Hospital
Boston,  MA
Live Q&A

Julia Skokowa , MD, Ph.D.
University Hospital Tuebingen
Tuebingen,  Germany
Novel Experimental Model of Stepwise Leukemogenesis Provides Therapeutic Opportunities for Severe Congenital Neutropenia

Julia Skokowa , MD, Ph.D.
University Hospital Tuebingen
Tuebingen,  Germany
Live Q&A

Agata Karolina Pastorczak , MD, PhD
Medical University of Lodz
Lodz,  Poland
Molecular Specific Features of Diffuse Large B-Cell Lymphoma in Children with Nijmegen Breakage Syndrome

Agata Karolina Pastorczak , MD, PhD
Medical University of Lodz
Lodz,  Poland
Live Q&A

Moderator:

Lucy A. Godley , MD, PhD
The University of Chicago
Chicago,  IL

December 10, 2021,  2:00 p.m. - 5:00 p.m. Eastern time

Older adults with hematologic disorders are a growing demographic yet remain understudied and are vulnerable to both disease and age-related morbidity and mortality. Improving the approach to care for older adults with hematologic disorders requires appreciation of the basic science of aging as well as differences in disease diagnosis, response, and tolerance to treatment.

This workshop aims to highlight key scientific advances in the aging and hematology field. In addition, the workshop aims to partner investigators within ASH with key participants in the broader geroscience community to advance hematology and aging research.

The workshop will utilize an interactive format and provide opportunities for early career investigators to share their research and demonstrate their leadership.

Workshop Schedule


Speaker:

Andrew S. Artz , MD,MS
City of Hope
Duarte,  CA
Introduction

Speaker:

Paige Green , PhD, MPH,FABMR
National Cancer Institute
Bethesda,  MD
NCI Perspective and Funding Opportunities

Moderator:

Andrew S. Artz , MD,MS
City of Hope
Duarte,  CA

Speakers:

Andrew S. Artz , MD,MS
City of Hope
Duarte,  CA
Moderator Introduction

Isabel Beerman , PhD
National Institute on Aging, NIH
Baltimore,  MD
Epigenetic Analysis on Young and Aged Hematopoietic Stem Cells

Kristina Kirschner , PhD
CRUK Beatson Institute
Bearsden,  United Kingdom
Longitudinal Dynamics of Clonal Hematopoiesis Identifies Gene-Specific Fitness Effects

Moderator:

Ashley E. Rosko , MD
The Ohio State University
Columbus,  OH

Speakers:

Ashley E. Rosko , MD
The Ohio State University
Columbus,  OH
Moderator Introduction

Curtis J Henry , PhD
Emory University School of Medicine
Atlanta,  GA
Delineating the Impact of Interleukin-37 on Anti-Cancer Immunity in Aged Backgrounds

Amina Abdul-Aziz , PhD
University of Cincinnati
Cincinnati,  OH
Senescence and Aging in the AML Microenvironment

Michaela R Reagan , PhD
Maine Medical Center Research Institute
South Portland,  ME
Bone Marrow Adipocytes in Aging and Multiple Myeloma

Moderators:

Heidi D. Klepin , MD,MS
Wake Forest School of Medicine
Winston Salem,  NC

Shakira J. Grant , MBBS
The University of North Carolina at Chapel Hill
Chapel Hill,  NC

Speakers:

Shakira J. Grant , MBBS
Pennsylvania Hospital
Chapel Hill,  NC
Moderator Introduction

Reinhard Stauder , MD
Innsbruck Medical University
Innsbruck,  Austria
Integration of Patient-Reported and Patient-Oriented Factors in Health Care of Older Patients with Myelodysplastic Syndromes

Philip H. Imus , MD
Columbia University
Baltimore,  MD
Aging, Myeloid Recovery, and Resilience after Allogeneic BMT

Alessandra Tucci , MD
Department of Hematology, ASST Spedali Civili
Brescia,  Italy
Prognostication By Geriatric Assessment in Hodgkin Lymphoma

Lisa K. Hicks , MD, MSc
Co-Chair of the ASH RC COVID-19 Registry Malignant Task Force
D.C.,  WA
Exploring the Impact of Advanced Age on COVID19 Outcomes and Treatment Patterns in the ASH RC COVID-19 Malignant Registry

Moderator:

Heidi D. Klepin , MD,MS
Wake Forest School of Medicine
Winston Salem,  NC

Speaker:

Heidi D. Klepin , MD,MS
Wake Forest School of Medicine
Winston Salem,  NC
Closing Remarks

December 10, 2021,  2:00 p.m. - 5:00 p.m. Eastern time

Pregnancy is a unique biologic state characterized by changes in coagulation system and immune tolerance. This workshop fills a gap in understanding physiologic changes in pregnancy and their interplay in development and course of hematologic diseases.

Autoimmunity can complicate pregnancy or be triggered by maternofetal antigenic disparity. Autoimmune hemolytic anemia is a rare and unique complication of pregnancy. Evolving evidence is pointing to a role of excessive complement activation in pathogenesis of pregnancy complications such as APLS, CM-HUS and HELLP syndrome. Endothelial damage in COVID-19 infection can trigger activation of coagulation and complement system in pregnancy leading to thrombosis and pregnancy loss. More recently SARS-CoV-2 vaccination has been associated with unique hematologic complications.

Advances in prenatal testing allow detection of predisposition to development of pregnancy associated diseases such as FNAIT; use of cell-free DNA allows early non-invasive identification of fetal genetic disorders such as hemophilia. Progress in gene editing methodologies hold the potential of early correction of the genetic defects in hemophilia and other disorders.

This workshop will serve as an introduction to the new scientific discoveries in this arena.

Workshop Schedule


Moderators:

Shannon M. Bates , MD,FRCPC,MSc
McMaster University
Hamilton,  ON, Canada

Irina Murakhovskaya , MD
MONTEFIORE HOSP & MED CTR
Brooklyn,  NY

Moderator:

Shruti Chaturvedi , MBBS
Johns Hopkins University School of Medicine
Baltimore,  MD

Speakers:

Shruti Chaturvedi , MBBS
Johns Hopkins University School of Medicine
Baltimore,  MD
Moderator Introduction

Bruno Fattizzo , MD
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico e Università degli Studi
Milan,  Italy
Autoimmune Hemolytic Anemia in Pregnancy

Fadi Fakhouri
University of Lausanne
Lausanne,  Switzerland
AHUS and Pregnancy

Shruti Chaturvedi , MBBS
Johns Hopkins University School of Medicine
Baltimore,  MD
Emerging Evidence on Preeclampsia and APLS

Moderator:

Menaka Pai , BSc,MD,FRCPC,MSc
McMaster University
Hamilton,  Canada

Speakers:

Menaka Pai , BSc,MD,FRCPC,MSc
McMaster University
Hamilton,  ON, Canada
Moderator Introduction

A. Kinga Malinowski , MD
Mt. Sinai Hospital
Toronto,  ON, Canada
Hematologic Aspects of COVID in Pregnancy

Menaka Pai , BSc,MD,FRCPC,MSc
McMaster University
Hamilton,  ON, Canada
Hematologic Complications of COVID Vaccination

Moderator:

Henny H. Billett , MD, MSc
Montefiore Medical Center, Albert Einstein College of Medicine
Bronx,  NY

Speakers:

Henny H. Billett , MD, MSc
Montefiore Medical Center, Albert Einstein College of Medicine
Bronx,  NY
Moderator Introduction

Craig D. Seaman
University of Pittsburgh
Pittsburgh,  PA
Next Generation Sequencing and Non-Invasive Prenatal Testing

Lani Lieberman , MD
University of Toronto
Toronto,  ON, Canada
Fetal and Neonatal Alloimmune Thrombocytopenia

David Stitelman , MD
Yale School of Medicine
New Haven,  CT
Prenatal Gene Therapy in Hematologic Disorders

Moderators:

Irina Murakhovskaya , MD
MONTEFIORE HOSP & MED CTR
Brooklyn,  NY

Shannon M. Bates , MD,FRCPC,MSc
McMaster University
Hamilton,  ON, Canada

December 10, 2021,  2:00 p.m. - 5:00 p.m. Eastern time

Venous thromboembolism (VTE) is the second leading cause of death in patients with cancer and cancer patients are the highest risk group for developing VTE. Despite considerable epidemiologic research, the mechanism of thrombosis in cancer is poorly understood.

This interactive workshop will discuss gaps in knowledge and ongoing investigations into how the coagulation system affects cancer progression and how therapy can modulate risk in myeloproliferative neoplasms and solid tumors.

This workshop will also provide a unique forum to discuss the mechanisms of thrombosis in hematologic malignancies, a topic that bridges malignant and non-malignant hematology within ASH.

Workshop Schedule


Moderators:

Lisa Baumann Kreuziger , MD
Versiti Blood Center of Wisconsin
Menomonee Falls,  WI

Jeffrey I. Zwicker , MD
Beth Israel Deaconess Medical Center Harvard Medical School
Boston,  MA

Moderators:

Alisa S. Wolberg , PhD
University of North Carolina At Chapel Hill
Chapel Hill,  NC

Christophe Dubois , PhD
Aix Marseille Université
Marseille,  France

Speakers:

Alisa S. Wolberg , PhD
University of North Carolina At Chapel Hill
Chapel Hill,  NC
Moderator Introduction

Westrick J Randal , PhD
oakland university
rochester hills,  MI
PAI-2 Deficiency and Accelerated Tumor Growth

Westrick J Randal , PhD
Oakland University
rochester hills,  MI
Q&A

Paul Jurasz
University of Alberta
Edmonton,  AB, Canada
Platelets and Pdl-1

Paul Jurasz
University of Alberta
Edmonton,  AB, Canada
Q&A

Claudine S Bonder , PhD
Hanson Institute, Institute of Medical and Veterinary Science
Adelaide,  SA, Australia
Platelets and Vasculogenic Mimicry By Cancer Cells

Claudine S Bonder , PhD
University of South Australia
Adelaide,  SA, Australia
Q&A

Moderators:

Mary Cushman , MD
Larner College of Medicine at the University of Vermont
Colchester,  VT

Cihan Ay
Medical University of Vienna
Vienna,  Austria

Speakers:

Mary Cushman , MD
Larner College of Medicine at the University of Vermont
Colchester,  VT
Moderator Introduction

Nadim Tawil , PhD
McGill University
Montreal,  QC, Canada
Podoplanin and Procoagulant Extracellular Vesicles in Glioma

Nadim Tawil , PhD
McGill University
Montreal,  QC, Canada
Q&A

Simon Mantha , MD,MPH
Memorial Sloan Kettering Cancer Center
New York,  NY
Genomic Profiling and Thrombosis in Cancer

Simon Mantha , MD,MPH
Memorial Sloan Kettering Cancer Center
New York,  NY
Q&A

Marc Carrier , MD
University of Ottawa
Ottawa,  ON, Canada
Growth Differentiation Factor-15 and Bleeding in Cancer

Marc Carrier , MD
University of Ottawa
Ottawa,  ON, Canada
Q&A

Moderators:

Ayalew Tefferi , MD
Mayo Clinic
Rochester,  MN

Casey L. O'Connell , MD
University of Southern California
Los Angeles,  CA

Speakers:

Casey L. O'Connell , MD
University of Southern California
Los Angeles,  CA
Moderator Introduction

Anish V. Sharda , MBBS
Harvard Medical School
Brookline,  MA
Protein Disulfide Isomerase and Thrombosis in MPN

Anish V. Sharda , MBBS
Harvard Medical School
Brookline,  MA
Q&A

Radhika Gangaraju , MD
University Of Alabama
Birmingham,  AL
HIF-Regulated Genes and Thrombosis in MPN

Radhika Gangaraju , MD
University Of Alabama
Birmingham,  AL
Q&A

Anandi Krishnan , PhD
Stanford University School of Medicine
Palo Alto,  CA
Thromboinflammatory Signatures in MPN

Anandi Krishnan , PhD
Stanford University School of Medicine
Palo Alto,  CA
Q&A

Moderators:

Lisa Baumann Kreuziger , MD
Versiti, Blood Research Institute
Milwaukee,  WI

Jeffrey I. Zwicker , MD
Beth Israel Deaconess Medical Center Harvard Medical School
Boston,  MA

Speakers:

Jeffrey I. Zwicker , MD
Beth Israel Deaconess Medical Center Harvard Medical School
Boston,  MA
Moderator Introduction

Yohei Hisada , Ph.D.
University of North Carolina at Chapel Hill
Chapel Hill,  NC
Mechanisms of Hypercoagulability in Different Types of Acute Leukemia: Roles of Tissue Factor-Positive and Phosphatidylserine-Positive Extracellular Vesicles

Yohei Hisada , Ph.D.
University of North Carolina At Chapel Hill
Chapel Hill,  NC
Q&A

Alok A Khorana , MD
CLEVELAND CLINIC - US
Cleveland,  OH
Biomarker Signatures in Cancer Patients with and without Venous Thromboembolism Events: A Substudy of Cassini

Alok A Khorana , MD
CLEVELAND CLINIC - US
Cleveland,  OH
Q&A

Ana Luisa Palacios-Acedo , MD,MSc
Aix-Marseille Université
Marseille,  France
Tipping the Hemostatic Balance in Cancer: A Multi-Player Game

Ana Luisa Palacios-Acedo , MD,MSc
Aix-Marseille Université
Marseille,  France
Q&A

Moderators:

Jeffrey I. Zwicker , MD
Beth Israel Deaconess Medical Center Harvard Medical School
Boston,  MA

Lisa Baumann Kreuziger , MD
Versiti Blood Center of Wisconsin
Menomonee Falls,  WI

December 10, 2021,  2:00 p.m. - 5:00 p.m. Eastern time

The workshop will cover the basic science of myeloid development and there will be no presentations on clinical/treatment strategies. The research that will be presented will utilize the tools of molecular biology, biochemistry, and animal models to address these topics. The research discussed will not include purely clinical, epidemiologic, or population-based approaches.

Workshop Schedule


Moderators:

Ross L. Levine , MD
Memorial Sloan Kettering Cancer Center
New York,  NY

Patricia Ernst , PhD
University of Colorado Denver, Anschutz Medical Campus
Aurora,  CO

Moderator:

Eric Pietras , PhD
University of Colorado
Aurora,  CO

Speakers:

Eric Pietras , PhD
University of Colorado
Aurora,  CO
Moderator Introduction

Yoon-A Kang , PhD
Washington University School of Medicine
St. Louis,  MO
Secretory MPP3 Reinforce Myeloid Differentiation Trajectory and Amplify Myeloid Cell Production

Yoon-A Kang , PhD
Washington University School of Medicine
New York,  NY
Q&A

Robert Signer , PhD
UC San Diego
La Jolla,  CA
Crosstalk between Autophagy and the Proteasome Coordinates Hematopoietic Stem Cell Quiescence, Proteostasis and Cell Fate Determination

Robert Signer , PhD
Moores Cancer Center
La Jolla,  CA
Q&A

Kevin Rouault-Pierre , PhD
Barts Cancer Institute, Queen Mary University of London
London,  United Kingdom
SF3B1 Mutation in Myelodysplasia Induces Depletion of Key Substrates of the Heme Synthesis

Kevin Rouault-Pierre , PhD
Barts Cancer Institute, Queen Mary University of London
London,  United Kingdom
Q&A

Katie L Kathrein , PhD
University of South Carolina
Columbia,  SC
Ing4-Deficiency Enhances Hematopoietic Stem Cell Quiescence and Confers Resistance to Inflammatory Stress

Katie L Kathrein , PhD
University of South Carolina
Columbia,  SC
Q&A

Moderator:

Ulrich G. Steidl , MD,PhD
Albert Einstein College of Medicine
Bronx,  NY

Speakers:

Ulrich G. Steidl , MD,PhD
Albert Einstein College of Medicine
Bronx,  NY
Moderator Introduction

Nina Cabezas-Wallscheid , PhD
Max-Planck-Institute of Immunobiology and Epigenetics
Freiburg,  Germany
Multilayer-Omics Analysis Reveals a Non-Classical Retinoic Acid Receptor Signaling Axis That Regulates Hematopoietic Stem Cell Identity

Nina Cabezas-Wallscheid , PhD
Max-Planck-Institute of Immunobiology and Epigenetics
Freiburg,  Germany
Q&A

Vikram R Paralkar , MD
University of Pennsylvania
Philadelphia,  PA
An Atlas of Hematopoietic Transcription Factor Binding to rDNA Reveals a Role for CEBPA in rRNA Regulation

Vikram R Paralkar , MD
University of Pennsylvania
Philadelphia,  PA
Q&A

Kristy Stengel , PhD
Albert Einstein College of Medicine
Bronx,  NY
Targeted Transcription Factor Degradation Defines Gene Networks and Mechanism of Action

Kristy Stengel , PhD
Albert Einstein College of Medicine
Bronx,  NY
Q&A

Stanley C Lee , PhD
Fred Hutchinson Cancer Research Center
Seattle,  WA
Spliceosome Mutant Leukemias Are Preferentially Sensitive to PARP1 Inhibition

Stanley C Lee , PhD
Fred Hutchinson Cancer Research Center
Seattle,  WA
Q&A

Moderator:

Benjamin L. Ebert , MD
Department of Medical Oncology, Dana-Farber Cancer Institute
Boston,  MA

Speakers:

Benjamin L. Ebert , MD
Department of Medical Oncology, Dana-Farber Cancer Institute
Boston,  MA
Moderator Introduction

Shruti Bhatt , PhD
National University of Singapore
Singapore,  Singapore
Unraveling Basis of Resistance to Acute Myeloid Leukemia Therapy

Shruti Bhatt , PhD
National University of Singapore
Singapore,  Singapore
Q&A

Liling Wan , PhD
University of Pennsylvania
Philadelphia,  PA
Targeting Chromatin Reader-Mediated Transcriptional Programs in Acute Myeloid Leukemia.

Liling Wan , PhD
University of Pennsylvania
Philadelphia,  PA
Q&A

Julie-Aurore Losman , MD, PhD
Dana Farber Cancer Institute
Boston,  MA
R)-2-Hydroxyglutarate Inhibits KDM5 Histone Lysine Demethylases to Drive Tumorigenesis in IDH-Mutant Cancers

Julie-Aurore Losman , MD, PhD
Dana Farber Cancer Institute
Boston,  MA
Q&A

Paolo Gallipoli , MD
University of Cambridge
London,  United Kingdom
Leveraging Metabolic Dependencies to Overcome Therapy Resistance in AML

Paolo Gallipoli , MD
University of Cambridge
London,  United Kingdom
Q&A

Moderator:

Claudia Lengerke , MD
University Hospital Tübingen
Tübingen,  Germany

Speakers:

Claudia Lengerke , MD
University Hospital Tübingen
Tübingen,  Germany
Moderator Introduction

Courtney L Jones , PhD
University of Toronto
Toronto,  ON, Canada
SIRT3 Inhibition Targets Leukemia Stem Cells By Disrupting Lipid Metabolism

Courtney L Jones , PhD
University of Toronto
Toronto,  ON, Canada
Q&A

Raajit Rampal , MD, PhD
Memorial Sloan Kettering Cancer Institute
New York,  NY
BMP/SMAD Pathway As a Mediator of Leukemic Transformation of Tp53 Mutant MPNs

Raajit Rampal , MD, PhD
Memorial Sloan Kettering Cancer Institute
New York,  NY
Q&a

Shannon McKinney-Freeman , PhD
St. Jude Children's Research Hospital
Memphis,  TN
Murine Fetal Bone Marrow Does Not Support Functional Hematopoietic Stem and Progenitor Cells until Birth

Shannon McKinney-Freeman , PhD
St. Jude Children's Research Hospital
Memphis,  TN
Q&A

Jan-Henning Klusmann , MD
University Hospital Frankfurt
Frankfurt (Main),  Germany
A Fetal Origin of Leukemia: Deciphering the Role of RUNX1 Isoforms in Trisomy 21 Associated Leukemogenesis

Jan-Henning Klusmann , MD
University Hospital Frankfurt
Frankfurt (Main),  Germany
Q&A

Moderators:

Patricia Ernst , PhD
University of Colorado Denver, Anschutz Medical Campus
Aurora,  CO

Ross L. Levine , MD
Memorial Sloan Kettering Cancer Center
New York,  NY

December 10, 2021,  2:00 p.m. - 5:00 p.m. Eastern time

Clinical trials are a major intersection between discovery basic research and clinical applications. An expanding array of therapeutic opportunities have been made possible by advances in genomics and precision medicine, thus the clinical research enterprise needs to be capable of testing more therapies or combinations of therapies more efficiently and at a lower total cost.

To foster the clinical research enterprise, there is a need to address how clinical trials are streamlined and prioritized to improve efficiency, safety, and generalizability, while preserving scientific integrity and unbiased efficacy assessments. This is an area where basic scientists and clinicians in hematology can actively collaborate.

This workshop will foster these collaborations in a setting that addresses roadblocks to streamlining clinical trial design and execution.

Workshop Schedule


Moderator:

Fangxin Hong , PhD
Pfizer
Cambridge,  MA

Moderators:

Willem E. Fibbe , MD, PhD
Leiden Univ. Medical Ctr.
Leiden,  Netherlands

Jeffrey Weitz
McMaster University
Hamilton,  ON, Canada

Speakers:

Willem E. Fibbe , MD, PhD
Leiden Univ. Medical Ctr.
Leiden,  Netherlands
Moderator Introduction

Richard F. Little , MD,MPH
National Cancer Institute
Washington,  DC
Streamlining and Prioritizing Clinical Trials – Overview

Yoji Sato , PhD
National Institute of Health Sciences
Kawasaki,  Japan
Regulatory Perspective - International

Angelo De Claro , MD
US Food and Drug Administration
Bethesda,  MD
Regulatory Perspective - US

Malte Peters , MD
Morphosys AG
Planegg,  Bavaria, Germany
Industry Perspective

Moderators:

Alex F. Herrera , MD
City of Hope
Duarte,  CA

Sonali M. Smith , MD
University of Chicago
Chicago,  IL

Speakers:

Alex F. Herrera , MD
City of Hope
Duarte,  CA
Moderator Introduction

David P. Steensma , MD
Novartis Institutes of Biomedical Research
Cambridge,  MA
Enhance the Interplay between Pre-Clinical and Clinical Research - from Bench to Bedside

Kannan Natarajan , PhD
Pfizer Inc.
Peapack,  NJ
Better Data Is Key

Megan Othus , PhD
Fred Hutchinson Cancer Research Center
Seattle,  WA
Innovative Trial Design

Moderators:

Kristen M. Sanfilippo , MD
Washington University in St. Louis School of Medicine
Chesterfield,  MO

Neil Goldenberg , MD,PhD
All Children's Hospital Johns Hopkins Medicine
Saint Petersburg,  FL

Speakers:

Kristen M. Sanfilippo , MD
Washington University in St. Louis School of Medicine
Chesterfield,  MO
Moderator Introduction

Uma Borate , MD
The Ohio State University
Columbus,  OH
Expediting Time from Concept to Enrollment

Ryan Zarychanski , MD,MSc,FRCPC
Cancercare Manitoba University of Manitoba
Winnipeg,  MB, Canada
Novel Methods in Trial Design and Global Collaboration: Lessons from COVID-19 That Are Relevant to Patients with Hematologic Disorders

Jean M Connors , MD
Brigham %26 Women's Hosp./Dana Farber Cancer Inst.
Boston,  MA
Prioritizing the Patients - Patients Are a Virtue

Moderator:

Fangxin Hong , PhD
Pfizer
Cambridge,  MA

December 10, 2021,  2:00 p.m. - 5:00 p.m. Eastern time

Sickle cell disease (SCD) is the most common inherited blood disorder worldwide. Current therapeutic options are limited. However, promising drug and gene therapy related therapies renewed interest in treatment for SCD and other hemoglobinopathies. The recent cases of MDS and AML adverse events observed in patients treated with gene therapy suggest that optimization of many aspects of this therapy are needed. With the discovery of CRISPR/Cas9 system, the genome can be edited, and mutations corrected directly. However, even with this approach, current strategies require conditioning and bone marrow transplant of the corrected cells. Therefore, both gene addition and genome editing will benefit from novel techniques that may reduce the toxicity associated with conditioning and hematopoietic stem cell (HSC) manipulation.

This workshop will discuss the current challenges in gene addition and genome editing of HSC, preclinical barriers, and safety concerns. Representatives will be invited to discuss how the recent cases of MDS, and AML are shaping their policy around gene therapy and gene editing and other experts will be invited to discuss the Relevant endpoints and outcomes measures of these new therapies and initiatives to accelerate cure will be presented and discussed.

Workshop Schedule


Moderators:

Stefano Rivella , PhD
Children’s Hospital of Philadelphia
Philadelphia,  PA

Mitchell J. Weiss , MD, Ph.D
St. Jude Children’s Research Hospital
Memphis,  TN

Moderators:

Alexis A. Thompson , MD, MPH
Northwestern University
Chicago,  IL

Giuliana Ferrari , PhD
San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute
Milan,  Italy

Speakers:

Giuliana Ferrari , PhD
San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute
Milan,  Italy
Moderator Introduction

Wendy W Pang , MD,PhD
Jasper Therapeutics, Inc
Redwood City,  CA
Potential Alternatives to Myeloablative Chemotherapy Conditioning

Punam Malik , MD
Cincinnati Children's Hosp.
Cincinnati,  OH
Gamma-Globin Gene Addition

Annarita Miccio , PhD
Université de Paris, Imagine Institute, Laboratory of chromatin and gene regulation during development, INSERM UMR1163, 75015
Paris,  France
Creating HPFH Via Editing

Laura Breda , PhD
The Children's Hospital of Philadelphia
Philadelphia,  PA
Novel Vector Modifications to Improve Synthesis of Curative Hemoglobins

Moderators:

John F. Tisdale , MD
National Institutes of Health
Bethesda,  MD

Linzhao Cheng , PhD
University of Science and Technology of China
Hefei,  China

Speakers:

Linzhao Cheng , PhD
University of Science and Technology of China
Hefei,  China
Moderator Introduction

Lachelle D. Weeks , MD,PhD
Dana Farber Cancer Institute
Boston,  MA
Development and Identification of Clonal Hematopoiesis

Courtney D. Fitzhugh , MD
NIH (Hematology)
Bethesda,  MD
Clonal Hematopoiesis in SCD

Shengdar Q. Tsai , PhD
St. Jude Children's Research Hospital
Memphis,  TN
Genotoxicities Associated with Genome Editing, Including SCD

Peter W. Marks , MD, PhD
FDA
Washington,  DC
FDA Position on Addressing Genome Toxicities in SCD Related Gene Therapy Trials

Moderators:

Matthew H. Porteus , MD, PhD
Stanford School of Medicine
Stanford,  CA

Kim Smith-Whitley , MD
Children's Hospital of Philadelphia
Philadelphia,  PA

Speakers:

Kim Smith-Whitley , MD
Children's Hospital of Philadelphia
Philadelphia,  PA
Moderator Introduction

Gerd A. Blobel , MD, PhD
Children's Hospital of Philadelphia
Philadelphia,  PA
Targeting the HbF Pathway

Jonathan S Yen , PhD
St. Jude Children's Research Hospital
Memphis,  TN
Base Editing for SCD

Andre Lieber , MD, PhD
University of Washington
Seattle,  WA
In Vivo Gene Editing for SCD

Donna S. Neuberg , ScD
Dana-Farber Cancer Institute
Boston,  MA
ASH Real World Evidence (RWE) Initiative on SCD

Moderators:

Stefano Rivella , PhD
Children’s Hospital of Philadelphia
Philadelphia,  PA

Mitchell J. Weiss , MD, Ph.D
St. Jude Children’s Research Hospital
Memphis,  TN

December 10, 2021,  2:00 p.m. - 5:00 p.m. Eastern time

This workshop will focus on technologies/diagnostics that are specific for acquired abnormalities in hematological malignancy (e.g., ctDNA and MRD testing). In addition, it will address real world application and implementation of new molecular diagnostic technologies and their translation into practice rather than the more biological/disease modelling focus of the germline predisposition workshop.

Workshop Schedule


Moderators:

Piers Blombery , MBBS
Peter MacCallum Cancer Centre
Melbourne,  Australia

Torsten Haferlach , MD
MLL Munich Leukemia Laboratory
Munich,  Germany

Moderator:

Torsten Haferlach , MD
MLL Munich Leukemia Laboratory
Munich,  Germany

Speakers:

Torsten Haferlach , MD
MLL Munich Leukemia Laboratory
Munich,  Germany
Moderator Introduction

Wendy N. Erber , MD,PhD,FRCPA,FRCPath,MBA
University of Western Australia
Crawley W.A.,  WEA, Australia
Chromosomal Analysis of Immunophenotyped Cells in Suspension By Imaging Flow Cytometry (“Immuno-flowFISH”)

Aziz Nazha
Amazon Web Services
Cleveland,  OH
Artificial Intelligence in Diagnostic Hematology

Linda B Baughn , PhD
Mayo Clinic
Rochester,  MN
Detection of Structural Variants and Copy Number Abnormalities By NGS in Hematologic Malignancies: Is It Time to Replace FISH and Chromosomes?

Moderator:

David M. Kurtz , MD,PhD
Stanford University
Stanford,  CA

Speakers:

David M. Kurtz , MD,PhD
Stanford University
Stanford,  CA
Moderator Introduction

David M. Kurtz , MD,PhD
Stanford University
Stanford,  CA
Novel Technologies in Circulating Tumor DNA

Imogen Caldwell , MBBS
Peter MacCallum Cancer Centre
Melbourne,  VIC, Australia
Circulating Tumor DNA Measurements Correlate with Disease Burden and Response in Patients Undergoing CAR T-Cell Therapy

Piers Blombery , MBBS
Peter MacCallum Cancer Centre
Melbourne,  Australia
Case Presentations - Clinical Utility of Circulating Tumor DNA in the Real World?

Moderator:

Ella R Thompson , PhD, BSc
Peter MacCallum Cancer Centre
Melbourne,  Australia

Speakers:

Ella R Thompson , PhD, BSc
Peter MacCallum Cancer Centre
Melbourne,  VIC, Australia
Moderator Introduction

Andrew H. Wei , MBBS,PhD
The Alfred Hospital
Melbourne,  VIC, Australia
MRD Directed Therapy - a New Frontier in AML

Ing-Soo Tiong
Peter MacCallum Cancer Centre
Melbourne,  VIC, Australia
Ultra-Deep NGS for MRD Assessment in CEBPA Mutated AML

Michael Heuser , MD
Hannover Medical School
Hannover,  Germany
Standardization of NGS-MRD

Moderator:

Kilannin Krysiak , PhD
Washington University In St Louis
Saint Louis,  MO

Speakers:

Kilannin Krysiak , PhD
Washington University In St Louis
Saint Louis,  MO
Moderator Introduction

Malachi Griffith , PhD
Washington University in St. Louis
St. Louis,  MO
A Clinical Genome Resource for Somatic Variant Interpretation in Cancer

Jennelle C. Hodge , PhD
Indiana University
Indianapolis,  IN
The Compendium of Cancer Genome Aberrations (CCGA): Becoming a Global Hub for WHO Classification of Tumours-Based Clinical Cancer Interpretation

Daniel MacArthur
Garvan Institute of Medical Research
Darlinghurst,  NSW, Australia
Creating Global Harmonized Resources for Understanding Population Genetic Variation

Moderators:

Piers Blombery , MBBS
Peter MacCallum Cancer Centre
Melbourne,  Australia

Torsten Haferlach , MD
MLL Munich Leukemia Laboratory
Munich,  Germany

December 10, 2021,  2:00 p.m. - 5:00 p.m. Eastern time

The area of immunotherapy in lymphoid malignancies has led to multiple new treatments. This proliferation of scientific knowledge has led to multiple potential new treatments including new immune checkpoint blockade therapies, novel T-cell approaches, agents targeting monocytes and macrophages, as well as new approaches inhibiting immune receptor (such as Toll-like receptors) and cytokine signaling.

This workshop seeks to address the use of immunological approaches to lymphoid malignancies while maintaining optimal immune function. The workshop will focus on the following three areas: a) lymphoid malignancies; b) immune system and tumor microenvironment; and c) current basic science to identify “what’s new” and predict “what’s next” in the world of immunotherapy.

This year’s workshop will have the theme of Molecules versus Cells – Round 2. It will specifically highlight the impact of immunologically active drugs, in comparison to cellular therapies, on lymphoid malignancies and discuss how these agents or cellular approaches may change clinical practice in the future. The workshop will address how novel targets, molecules, cellular therapies or biomarkers may become relevant in practice in the future.

Workshop Schedule


Moderators:

Stephen M. Ansell , MD, PhD
Mayo Clinic
Rochester,  MN

Ronald Levy , MD
Stanford University School of Medicine
Stanford,  CA

Moderators:

Stephen M. Ansell , MD, PhD
Mayo Clinic
Rochester,  MN

Ronald Levy , MD
Stanford University School of Medicine
Stanford,  CA

Speakers:

Stephen M. Ansell , MD, PhD
Mayo Clinic
Rochester,  MN
Moderator Introduction

Natalie S Grover , MD
University of North Carolina at Chapel Hill
Chapel Hill,  NC
Current Results with CD30 CAR T-Cells in Hodgkin Lymphoma

Natalie S Grover , MD
University of North Carolina at Chapel Hill
Chapel Hill,  NC
Q&A

Graham P. Collins , MD, DPhil
Oxford University Hospitals NHS Foundation Trust
Oxford,  ENG, United Kingdom
Current Results with Camidanlumab Tesirine (Cami) in Hodgkin Lymphoma

Graham P. Collins , MD, DPhil
Oxford University Hospitals NHS Foundation Trust
Oxford,  ENG, United Kingdom
Q&A

Moderators:

Ronald Levy , MD
Stanford University School of Medicine
Stanford,  CA

Stephen M. Ansell , MD, PhD
Mayo Clinic
Rochester,  MN

Speakers:

Ronald Levy , MD
Stanford University School of Medicine
Stanford,  CA
Moderator Introduction

Crystal L. Mackall , MD
Stanford University School of Medicine
Stanford,  CA
Dual Targeted CAR T-Cells in B-Cell Lymphoma

Crystal L. Mackall , MD
Stanford University School of Medicine
Stanford,  CA
Q&A

Martin Hutchings
Rigshospitalet
Copenhagen,  Denmark
Bispecific Antibodies with Increased Target Binding – Does It Matter?

Martin Hutchings
Rigshospitalet
Copenhagen,  Denmark
Q&A

Moderators:

Stephen M. Ansell , MD, PhD
Mayo Clinic
Rochester,  MN

Ronald Levy , MD
Stanford University School of Medicine
Stanford,  CA

Speakers:

Ronald Levy , MD
Stanford University School of Medicine
Stanford,  CA
Moderator Introduction

LaQuisa C. Hill , MD
Baylor College of Medicine, Houston Methodist Hospital
Houston,  TX
Current Results with CD5/7/30 CAR T-Cells for T-Cell Lymphoma

LaQuisa C. Hill , MD
Baylor College of Medicine, Houston Methodist Hospital
Houston,  TX
Q&A

Paola Ghione , MD
Roswell Park Comprehensive Cancer Center
Buffalo,  NY
Immunotherapy in T-Cell Lymphomas – Targeting T-Cells and Macrophages

Paola Ghione , MD
Roswell Park Comprehensive Cancer Center
Buffalo,  NY
Q&A

Moderators:

Ronald Levy , MD
Stanford University School of Medicine
Stanford,  CA

Stephen M. Ansell , MD, PhD
Mayo Clinic
Rochester,  MN